Introduction
============

Parkinson's disease (PD) is a disabling neurodegenerative disease, which is progressive, and is caused by a loss of dopaminergic neurons in the substantia nigra ([@ref-27]). Onset is generally after the age of 40 years, and predominantly affects males, with an incidence that increases with age ([@ref-33]). In Taiwan, the prevalence was 84.8 per 100,000 in 2004, and 147.7 per 100,000 in 2011, with an annual growth rate of 7.9%. The highest prevalence was among individuals over 80 years of age. Over the past decade, Japan, France, and Israel have also reported similar findings ([@ref-23]).

Previously, several studies have emphasized inflammatory responses in the progression of PD ([@ref-12]; [@ref-26]), and have proposed that chronic conditions and infections, such as diabetes mellitus ([@ref-36]) and periodontal problems ([@ref-35]), resulting in inflammatory reactions, may be one of the etiological factors in the pathogenesis of PD. In a previous study, after adjustment for age, periodontal disease was significantly higher in men than women (56.4% vs. 38.4%) ([@ref-11]). Periodontal inflammatory disease (PID), which comprises two major forms, i.e., chronic gingivitis (CG) and chronic periodontitis (CP), is a form of peripheral inflammation with potentially systemic effects. It involves mechanisms mediated by periodontal pathogenic microbes and inflammatory responses. CG is primarily caused by accumulated dental bacterial plaque and may develop into CP ([@ref-1]). The products of periodontal pathogens cause host cells to generate and release pro-inflammatory mediators, such as IL-1, IL-6, TNF- α, and reactive oxygen species (ROS) ([@ref-10]) and the mediators might induce dopaminergic neuronal necrosis or apoptosis, PD initiation and progression, and then cause movement and cognitive disorders ([@ref-18]).

Periodontal bacterial cell wall components including Helicobacter pylori (HP), such as the endotoxin lipopolysaccharides (LPS) of Gram-negative strains, are well known as potent inflammatory agents. Bacterial LPS is widely used in model studies of PD induction. In addition, HP infection can aggravate the neurodegenerative process in PD ([@ref-19]; [@ref-25]; [@ref-31]). However, there is no direct evidence to date to indicate that PID plays a role in PD pathogenesis ([@ref-18]). Although few articles have addressed the relationship between periodontal problems and PD in cross-sectional studies ([@ref-2]; [@ref-7]; [@ref-24]; [@ref-27]) the cause-effect relationship remains unclear. In 2013, [@ref-22] first reported an increased risk of parkinsonism after CP in a cohort study. However, only patients with CP were enrolled in their cohort study and a lack of information of CG leaves the exact relationship between PID and PD unclear. Moreover, parkinsonism is a general term that not only indicates PD ([@ref-9]). Therefore, we here conducted a cohort study using the National Health Insurance Research Database (NHIRD) of Taiwan to determine the risk of developing PD after PID.

Materials & Methods
===================

Data sources
------------

The National Health Insurance Program (NHIP) was developed and managed for research purposes since 1995 and provides universal and comprehensive health care for about 99% of Taiwanese residents ([@ref-15]). The NHIRD data from 1996 to 2013 were selected. The data used in the present study were retrieved from the data of one million randomly selected subjects in the whole NHIRD, representing about 4.5% of the population from the entire NHIRD enrollee population ([@ref-16]). There was no significant difference in age and gender between theone million random-sampled data sets and enrollees in the NHIRD. The demographic information gathered included encrypted identification numbers, sex, dates of birth and death, diagnostic data, and procedures. The diagnostic data included the dates of dental procedures and the *International Classification of Diseases*, *Ninth Revision*, *Clinical Modification* (*ICD-9-CM*) diagnostic and procedure codes ([@ref-28]).

The study was approved by the Institutional Review Board (IRB) in Chung Shan Medical University (CS2-15071).

Study design and sampled participants
-------------------------------------

This study was a retrospective matched-cohort design. Patients who were aged ≥40 years, new diagnosed between January 1, 1997, and December 31, 2004, based on the ICD-9-CM diagnostic criteria code: 523.1 (CG) and 523.4 (CP), were recruited. In addition, each enrolled patient had been diagnosed at least at three outpatient clinics with PID (CG or/and CP) during a 1-year study period ([@ref-32]). Exclusion criteria were as follows: age and gender unknown, and PID diagnoses made before 1997. In addition, the patients being diagnosed with PD (ICD-9-CM code: 332.0) ([@ref-23]) before 1997 or before the first visit for PID were also excluded. In the interests of accuracy patients were excluded if they had not accessed health services for more than one year, as the NHIRD does not record deaths. A total of 5,396 patients with PID were recruited and 10,792 patients without PID were matched by gender, age, and index years as a control group, at a 1:2 ratio.

Both cohorts were followed from the index date until the PD diagnosis, death, or the end of December 31, 2013, whichever came first, as shown in [Fig. 1](#fig-1){ref-type="fig"}. The covariates included gender and age group (40--49, 50--59, 60--69, and ≥70 years). According to the definition of urbanization issued by the National Institutes of Health in Taiwan, all 365 townships in Taiwan are divided into seven clusters according to the following variables: population density (people/km^2^), the proportion of the population with college or above educational levels, population ratio of elderly people (over 65 years old), the population ratio of people who are agricultural workers and the number of physicians per 100,000 people. In the present study, we operationally defined townships of 1--2 clusters as level 1, 3--4 clusters as level 2, and 5--7 clusters as level 3 ([@ref-21]).

![Flowchart of cohort selection of patients from the National Health Research Institute.](peerj-05-3647-g001){#fig-1}

The PD-related comorbidities include hypertension (ICD-9-CM codes: 401.1, 401.9, 402.10, 402.90, 404.10, 404.90, 405.1, and 405.9), hyperlipidemia (ICD-9-CM codes: 272.0--272.9), chronic kidney disease (ICD-9-CM codes: 580, 581--589, 753, 403, 404, 250.4, 274.1, 440.1, 442.1, 447.3, 572.4, 642.1, and 646.2), depression (ICD-9-CM code: 311), stroke (ICD-9-CM codes: 433, 434, and 436) and traumatic brain injury (ICD-9-CM codes: 800--804, 850--854, 905.0, 950.1, 950.3, 907.0, 959.01, 959.9, 310.2, and V15.52) ([@ref-4]; [@ref-13]; [@ref-17]; [@ref-22]; [@ref-35]). We also recorded the Charlson Comorbidity Index (CCI), which contains 17 weighted comorbidities and was calculated for each participant ([@ref-5]).

Statistical analysis
--------------------

The *t*-test and chi-square test were used to compare the demographic and clinical characteristics of patients with PD vs. those without PID. Univariate and multivariate models were then used to calculate the hazard ratio (HR) and the 95% confidence interval (CI) with stratified Cox regression models. Multivariable models were adjusted for PD-related comorbidities, CCI score, and urbanization level. The incidence rate (IR) and incidence rate ratio (IRR) (per 100,000 person-years) was calculated by dividing the number of events of current PD by the person-years (PYs) observed for each patient. The Kaplan--Meier method was used to assess the survival probability in PD between the case and control cohorts. The log-rank test was used to compare their differences.

In sensitivity analysis, we identified patients with PID that occurred ≥1-year after the diagnosis of PID and the incidence of PD during the 5-year period after a diagnosis of CG and CP ([@ref-22]). We performed sensitivity analysis, excluding patients diagnosed with PD \< 1--5 years after a diagnosis of CG or CP, to ensure the stability and accuracy of the statistical model ([@ref-34]). All statistical analyses were performed in SAS version 9.3 (SAS Institute, Cary, NC, USA) and SPSS software version 22 (SPSS Inc., Chicago, IL, USA). Statistical significance was defined by a *p*-value \<0.05.

Results
=======

The baseline demographic characteristics at the beginning of the study were shown in [Table 1](#table-1){ref-type="table"}. The patients with PID had a higher prevalence of hyperlipidemia, depression, CCI score, and urbanization level than the control cohort. The mean ages for the case and control cohorts were 54.1 ± 10.5 and 54.2 ± 10.5 years, respectively. The mean follow-up time for the case and control cohorts was 11.9 ± 2.6 and 12.2 ± 2.6 years, respectively.
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###### Demographic characteristics of the study cohort at baseline.
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  Variable                 Total    Periodontal inflammatory disease   *p*-value                            
  ------------------------ -------- ---------------------------------- ----------- ------- -------- ------- ----------
  Total                    16,188   100                                5,396       100     10,792   100     
  Gender                                                                                                    
  Female                   7,461    46.09                              2,487       46.09   4,974    46.09   \>0.999
  Male                     8,727    53.91                              2,909       53.91   5,818    53.91   
  Age (years)                                                                                               
  40--49                   6,808    42.06                              2,269       42.05   4,539    42.06   \>0.999
  50--59                   4,610    28.48                              1,537       28.48   3,073    28.47   
  60--69                   2,939    18.16                              980         18.16   1,959    18.15   
  ≥70                      1,831    11.31                              610         11.3    1,221    11.31   
  Hypertension                                                                                              
  No                       7,461    46.09                              2,487       46.09   4,974    46.09   0.1834
  Yes                      8,727    53.91                              2,909       53.91   5,818    53.91   
  Hyperlipidemia                                                                                            
  No                       13,015   80.4                               4,198       77.8    8,817    81.7    \<0.0001
  Yes                      3,173    19.6                               1,198       22.2    1,975    18.3    
  Chronic kidney disease                                                                                    
  No                       11,256   69.53                              3,727       69.07   7,529    69.76   0.3651
  Yes                      4,932    30.47                              1,669       30.93   3,263    30.24   
  Depression                                                                                                
  No                       13,829   85.43                              4,522       83.8    9,307    86.24   \<0.0001
  Yes                      2,359    14.57                              874         16.2    1,485    13.76   
  Stroke                                                                                                    
  No                       13,434   82.99                              4,478       82.99   8,956    82.99   \>0.999
  Yes                      2,754    17.01                              918         17.01   1,836    17.01   
  Traumatic brain injury                                                                                    
  No                       13,517   83.5                               4,545       84.23   8,972    83.14   0.0773
  Yes                      2,671    16.5                               851         15.77   1,820    16.86   
  CCI score                                                                                                 
  0                        1,719    10.62                              541         10.03   1,178    10.92   0.0010
  1                        2,455    15.17                              747         13.84   1,708    15.83   
  2                        2,583    15.96                              872         16.16   1,711    15.85   
  ≥3                       9,431    58.26                              3,236       59.97   6,195    57.4    
  Urbanization level                                                                                        
  1                        10,479   64.73                              6,662       61.71   3,817    70.79   \<0.0001
  2                        4,337    26.79                              3,076       28.49   1,261    23.39   
  3                        1,372    8.48                               1,058       9.8     314      5.82    

**Notes.**

CCIcharlson Comorbidity Index

A total of 176 (3.26%) and 275 (2.55%) patients were diagnosed with PD in the case and control cohorts, respectively ([Fig. 1](#fig-1){ref-type="fig"}). [Table 2](#table-2){ref-type="table"} shows the Cox regression analysis of risk factors associated with development of PD. More people developed PD in the PID cohort than in the control cohort and the adjusted HR was 1.431 (95% CI \[1.141--1.794\], *p* = 0.002; [Table 2](#table-2){ref-type="table"}). Patients with hypertension, depression, stroke, traumatic brain injury and CCI score ≥3 tended to have a higher risk of development of PD and the adjusted HR was 1.746, 2.116, 2.257, 1.645 and 4.207 respectively (all *p* \< 0.05; [Table 2](#table-2){ref-type="table"}).
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###### Covariates associated with Parkinson's disease at the end of follow-up with univariate and multivariable Cox-regression analysis.
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  Variable                           Univariate analysis   Multivariable analysis                                          
  ---------------------------------- --------------------- ------------------------ ---------- ----------- --------------- ----------
  Periodontal inflammatory disease                                                                                         
  Control                            Reference                                                 Reference                   
  Case                               1.422                 1.165--1.737             0.0005     1.431       1.141--1.794    0.002
  Hypertension                                                                                                             
  No                                 Reference                                                 Reference                   
  Yes                                2.566                 1.727--3.813             \<0.0001   1.746       1.114--2.735    0.015
  Hyperlipidemia                                                                                                           
  No                                 Reference                                                 Reference                   
  Yes                                2.566                 1.727--3.813             \<0.0001   1.018       0.763--1.36     0.9019
  Chronic kidney disease                                                                                                   
  No                                 Reference                                                 Reference                   
  Yes                                1.358                 1.063--1.735             0.0144     0.992       0.746--1.32     0.9586
  Depression                                                                                                               
  No                                 Reference                                                 Reference                   
  Yes                                2.654                 1.995--3.53              \<0.0001   2.116       1.55--2.888     \<0.0001
  Stroke                                                                                                                   
  No                                 Reference                                                 Reference                   
  Yes                                2.981                 2.289--3.881             \<0.0001   2.257       1.693--3.007    \<0.0001
  Traumatic brain injury                                                                                                   
  No                                 Reference                                                 Reference                   
  Yes                                2.035                 1.548--2.676             \<0.0001   1.645       1.217--2.224    0.0012
  CCI score                                                                                                                
  0                                  Reference                                                 Reference                   
  1                                  3.778                 0.979--14.584            0.0538     3.433       0.85--13.873    0.0834
  2                                  4.202                 1.156--15.282            0.0293     2.829       0.753--10.635   0.1238
  ≥3                                 9.472                 2.821--31.808            0.0003     4.207       1.171--15.107   0.0276
  Urbanization level                                                                                                       
  1                                  Reference                                                 Reference                   
  2                                  1.288                 0.977--1.696             0.0722     1.230       0.905--1.671    0.1862
  3                                  1.187                 0.804--1.752             0.3891     1.133       0.713--1.799    0.5981

**Notes.**

CCICharlson Comorbidity IndexHRhazard ratioCIconfidence interval

[Table 3](#table-3){ref-type="table"} shows subgroups stratified by gender, age, comorbidities, CCI score and urbanization level during a 1-year period. The IRR of PD was significantly higher among the case cohort than it was among the control cohort, in the following subgroups: male gender, age ≥60 years, hypertension, stroke, CCI score 1, and CCI score ≥3. Both the patients with and without hyperlipidemia, chronic kidney disease, and traumatic brain injury in the case group were at higher risk of PD than were the control group. Level 1 and level 2 carried greater significant risk than did level 3 in terms of urbanization. However, PID subjects who were male, aged ≥70 years, hypertension, no hyperlipidemia, no depression, stroke, with/without chronic kidney disease, traumatic brain injury, CCI score ≥3, and the highest urbanization level 1, were associated with significant higher risk of PD after adjusting the HR.
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###### Incidence and hazard ratios of Parkinson's disease with periodontal inflammatory disease at the end of follow-up period, stratified by variables listed in the table with Cox-regression analysis.

![](peerj-05-3647-g005)

  Variable                 Periodontal inflammatory disease   IRR      95% CI   Adjusted HR   95% CI    *p*-value                                                                                                                   
  ------------------------ ---------------------------------- -------- -------- ------------- --------- ----------- ---------------------------------------- ------------ ----------------------------------------- --------------- --------
  Gender                                                                                                                                                                                                                            
  Female                   62                                 29,547   209.8    119           60,748    195.9       1.07                                     0.88--1.30   1.145                                     0.839--1.564    0.3932
  Male                     114                                34,501   330.4    156           70,786    220.4       1.50[^\*^](#table-3fn1){ref-type="fn"}   1.26--1.78   1.557[^\*^](#table-3fn1){ref-type="fn"}   1.216--1.993    0.0004
  Age (years)                                                                                                                                                                                                                       
  40--49                   5                                  27,514   18.2     18            56,114    32.1        0.57                                     0.32--1.01   0.716                                     0.264--1.946    0.5129
  50--59                   26                                 18,099   143.7    48            37,100    129.4       1.11                                     0.88--1.41   1.414                                     0.867--2.306    0.1657
  60--69                   64                                 11,575   552.9    107           23,884    448.0       1.23[^\*^](#table-3fn1){ref-type="fn"}   1.09--1.39   1.204                                     0.878--1.651    0.2483
  ≥70                      81                                 6,860    1180.8   102           14,437    706.5       1.67[^\*^](#table-3fn1){ref-type="fn"}   1.52--1.83   1.615[^\*^](#table-3fn1){ref-type="fn"}   1.198--2.177    0.0017
  Hypertension                                                                                                                                                                                                                      
  No                       17                                 23,513   72.3     24            46,242    51.9        1.39                                     0.97--1.99   1.563                                     0.815--2.997    0.1785
  Yes                      159                                40,534   392.3    251           85,292    294.3       1.33[^\*^](#table-3fn1){ref-type="fn"}   1.14--1.55   1.365[^\*^](#table-3fn1){ref-type="fn"}   1.115--1.671    0.0026
  Hyperlipidemia                                                                                                                                                                                                                    
  No                       133                                49,693   267.6    214           10,7219   199.6       1.34[^\*^](#table-3fn1){ref-type="fn"}   1.12--1.61   1.471[^\*^](#table-3fn1){ref-type="fn"}   1.180--1.833    0.0006
  Yes                      43                                 14,354   299.6    61            24,315    250.9       1.19[^\*^](#table-3fn1){ref-type="fn"}   1.01--1.41   1.097                                     0.739--1.629    0.6457
  Chronic kidney disease                                                                                                                                                                                                            
  No                       86                                 44,191   194.6    141           91,486    154.1       1.26[^\*^](#table-3fn1){ref-type="fn"}   1.02--1.56   1.363[^\*^](#table-3fn1){ref-type="fn"}   1.037--1.793    0.0266
  Yes                      90                                 19,857   453.2    134           40,049    334.6       1.35[^\*^](#table-3fn1){ref-type="fn"}   1.17--1.55   1.370[^\*^](#table-3fn1){ref-type="fn"}   1.044--1.797    0.0232
  Depression                                                                                                                                                                                                                        
  No                       113                                53,832   209.9    184           11,3417   162.2       1.29[^\*^](#table-3fn1){ref-type="fn"}   1.05--1.58   1.408[^\*^](#table-3fn1){ref-type="fn"}   1.108--1.788    0.0050
  Yes                      63                                 10,216   616.7    91            18,117    502.3       1.23[^\*^](#table-3fn1){ref-type="fn"}   1.09--1.38   1.313                                     0.946--1.822    0.1038
  Stroke                                                                                                                                                                                                                            
  No                       70                                 53,310   131.3    123           10,9094   112.7       1.16                                     0.90--1.49   1.209                                     0.896--1.633    0.2144
  Yes                      106                                10,737   987.2    152           22,440    677.4       1.46[^\*^](#table-3fn1){ref-type="fn"}   1.32--1.61   1.479[^\*^](#table-3fn1){ref-type="fn"}   1.149--1.904    0.0024
  Traumatic brain injury                                                                                                                                                                                                            
  No                       112                                54,111   207.0    186           10,9259   170.2       1.22[^\*^](#table-3fn1){ref-type="fn"}   1.00--1.49   1.213                                     0.956--1.539    0.1121
  Yes                      64                                 9,936    644.1    89            22,276    399.5       1.61[^\*^](#table-3fn1){ref-type="fn"}   1.42--1.82   1.690[^\*^](#table-3fn1){ref-type="fn"}   1.215--2.350    0.0018
  CCI score                                                                                                                                                                                                                         
  0                        1                                  6,346    15.8     2             14,132    14.2        1.11                                     0.54--2.27   1.495                                     0.025--88.223   0.8468
  1                        6                                  8,767    68.4     8             20,399    39.2        1.75[^\*^](#table-3fn1){ref-type="fn"}   1.18--2.59   2.139                                     0.711--6.439    0.1762
  2                        9                                  10,343   87.0     17            20,698    82.1        1.06                                     0.78--1.43   1.463                                     0.636--3.365    0.3706
  ≥3                       160                                38,591   414.6    248           76,305    325.0       1.28[^\*^](#table-3fn1){ref-type="fn"}   1.11--1.48   1.328[^\*^](#table-3fn1){ref-type="fn"}   1.084--1.626    0.0061
  Urbanization level                                                                                                                                                                                                                
  1                        124                                45,606   271.9    144           81,426    176.8       1.54[^\*^](#table-3fn1){ref-type="fn"}   1.27--1.86   1.467[^\*^](#table-3fn1){ref-type="fn"}   1.151--1.871    0.0020
  2                        44                                 14,747   298.4    84            37,197    225.8       1.32[^\*^](#table-3fn1){ref-type="fn"}   1.11--1.57   1.426                                     0.986--2.062    0.0593
  3                        8                                  3,695    216.5    47            12,911    364.0       0.59[^\*^](#table-3fn1){ref-type="fn"}   0.50--0.70   0.581                                     0.272--1.241    0.1606

**Notes.**

*p* \< 0.05.

CCICharlson Comorbidity IndexPYsperson-yearsIRincidence rate (per 10^5^ PYs)IRRincidence rate ratio (per 10^5^ PYs)CIconfidence intervalHRhazard ratio

Applying sensitivity analysis to the strategic evaluation by using the Cox proportional hazards regression model for examining the risk of PD after CG and CP were shown in [Table 4](#table-4){ref-type="table"}. We performed sensitivity analysis after excluding patients diagnosed with PD \< 1 and \<5 years after diagnosis of CG and CP. The association between CG/CP and PD remained consistent (adjusted HR of 1-year and 5-year was 1.431 and 1.395 respectively.)

[Figure 2](#fig-2){ref-type="fig"} shown the Kaplan--Meier for cumulative risk of PD in the case and control groups. The difference between the case and control groups reached statistical significance difference between the case and control group in the 1st year of follow-up (*p* \< 0.05 with log-rank test).

Discussion
==========

To the best of our knowledge, this is the first nationwide population-based matched-cohort study to find that patients with newly diagnosed PID had an increased risk of developing PD (adjusted HR = 1.431) regardless of comorbidities, CCI score, and urbanization level. Overall, our study found that hypertension, depression, stroke, traumatic brain injury, and CCI score ≥3 were independent risk factors for PD.

![Kaplan--Meier model based on the Cox-regression analysis for the cumulative risk of Parkinson's disease among the case and control cohort with the log-rank test.](peerj-05-3647-g002){#fig-2}
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###### Sensitivity analysis of Cox-regression model for Parkinson's disease.

![](peerj-05-3647-g006)

  Periodontal inflammatory disease   Crude HR   95% CI         *p*-value   Adjusted HR   95% CI         *p*-value
  ---------------------------------- ---------- -------------- ----------- ------------- -------------- -----------
  1-year period after a diagnosis    1.422      1.165--1.737   0.0005      1.431         1.141--1.794   0.002
  5-year period after a diagnosis    1.364      1.079--1.725   0.0095      1.395         1.067--1.825   0.015

**Notes.**

HRhazard ratioCIconfidence interval

Periodontal microorganisms mainly comprise the gram-negative bacteria with endotoxin LPS, which leads to breakdown of the blood brain barrier (BBB). PID can lead to the induction of pro-inflammatory cytokines, including IL-1, IL-6, and TNF-α. These cytokines can activate microglial cells, which produce nitric oxide and ROS, leading to death of dopaminergic neurons ([@ref-18]). Our findings showing increased PD after PID support the reports stating that LPS, produced by gram-negative bacteria, may be an important contributor to the development and progression of PD ([@ref-3]). Similar findings were reported from several studies, where the correlation between periodontal problems and PD were revealed. They reported that periodontal problems are frequently found in patients with PD by using cross-section observation, because these patients with PD progressively showed less self-care capability and reduced dental appointments ([@ref-2]; [@ref-7]; [@ref-24]; [@ref-27]; [@ref-29]). In addition, a previous study found that patients with PD frequently have oral gram-negative bacteria. Their oral flora differed considerably from that of healthy people ([@ref-14]). Moreover, patients with PD often suffer from xerostomia, drooling, and dysphagia, which impair their quality of life ([@ref-2]). Therefore, periodontal disease is also one of the important issues affecting the quality of life in patients with PD ([@ref-7]). Nonetheless the cause--effect relationship between periodontal problems and PD remained uncertain until [@ref-22] reported, using a cohort study, that revealed increased Parkinsonism five years following a diagnosis.

Unfortunately, patients with CG were not enrolled and the definite HR for a time-period less than 5 years after diagnosis of PID was not reported in their study. We emphasize the importance of enrolling CG because gingivitis is caused by accumulated dental-bacterial plaque and inflammation of gingiva, and CP may develop in PID. CG does not directly result in tooth loss and may be considered reversible with appropriate care. However, CP is always preceded by CG and any resulting clinical loss of attachment and alveolar bone loss due to CP cannot be reversed. In our study, we found that patients with PID (mainly CG and CP) had an almost 1.4-fold increased risk of developing PD, not only in the CP stage. Therefore, greater care should be paid, to educating the oral hygiene and plaque control methods for patients with PD because periodontal pathology presented a high prevalence in the early stages of gingivitis.

As shown in [Table 3](#table-3){ref-type="table"}, we found male gender, age ≥70 years, hypertension, stroke, traumatic brain injury, CCI score ≥3, and urbanization level 1 in patients with PID were significantly associated with the risk of developing PD. Our findings agree with recent studies which found that PD incidence was higher among males than females ([@ref-30]). The possible explanations suggested that women carry recessive susceptibility genes on the X chromosome, estrogen has neuroprotective effects, women have a lower rate of toxic exposure, and less incidence of traumatic brain injury, than men ([@ref-30]). The patients with and without chronic kidney disease were related with the increased risk of development in PD ([@ref-20]).

PID is a chronic inflammatory condition of the supporting structures of the teeth resulting from a dental plaque biofilm attached to teeth surfaces. Previous study has indicated the presence of a significant association between periodontitis and hyperlipidemia ([@ref-8]). According to an earlier study ([@ref-6]), we adjusted for the selected comorbidities including hyperlipidemia in the Cox-regression model. However, in the subgroups stratified by gender, age, comorbidities, CCI score and urbanization ([Table 3](#table-3){ref-type="table"}), the patients without hyperlipidemia were associated with a higher risk of developing PD (adjusted HR = 1.471). Therefore, further investigation will be required to confirm and clarify the mechanism.

Our results showed higher IRR and adjusted HR for urbanization level 1 (1.54 and 1.467, respectively) in the case group for developing PD. It may be explained by the urban--rural differences in terms of lifestyle, availability of medical resources, and convenience of medical access due to urban patients having better health care ([@ref-23]). We performed sensitivity analysis to evaluate the role of PID in the development of PD. We further demonstrated and confirmed the adjusted HR during the 1-year and 5-year follow-up period for individuals with PID were 1.431 and 1.395 relative to the control group. However, in a previous study, the patients exposed to CP had significantly greater adjusted HR than did the control group after the 5-year follow-up period ([@ref-22]). Based on our findings, we suggest that it is necessary to control inflammatory components of patients in the early phase, to potentially reduce the risk of PD.

Our research has the following advantages: (1) We applied a nationwide database and recruited a large number of sample sizes in highlighting the HR and IR over the 16-year long-term follow-up. (2) Taiwanese NHIRD provides continued coverage for the whole population of Taiwan and thus avoids selection bias in the cohorts, (3) the use of the NHIRD eliminates the need to minimize patients in the cohort that were lost to tracing, (4) in socio-demographic characteristics, it is easy to obtain geographically dispersed large samples, which avoids the estimated regional discrepancy ([@ref-21]), (5) we applied a rigorous definition to identify patients with PD (ICD-9-CM code: 332.0), such that statistical analysis would be more robust and reliable.

However, there were some limitations to our study (1) We excluded patients who had PD before tracing. However, we could not differentiate between primary and secondary Parkinsonism in analyzing NHIRD on the diagnostic code from a representative cohort ([@ref-23]), (2) we did not access medical records of all defined PID and PD cases, because all the medical records from the NHIRD was de-identified due to ethics approval. We had no clinical information regarding image findings, clinical photographs and examinations of the periodontal disease, laboratory data or treatment response in the defined patients. (3) Periodontal treatment in clinics, oral hygiene from caregivers improved education regarding good oral hygiene practices may help to prevent PD by reducing inflammation ([@ref-27]); however, personal details about periodontal therapy were not included in the NHIRD. (4) Finally, our methods to extract data from the NIHRD enable long-term follow-up periods of sufficiently large cohorts to correlate risk for PD in the context of PID and in the future, could incorporate additional factors such as environmental exposures, lifestyle (e.g., smoking) and genetic polymorphisms. Accurate risk assessment for PD in the context of PID is necessary if it is to influence healthcare planning and national health insurance policy.

Conclusions
===========

Individuals exposed to PID were 1.431 times more likely to develop PD than those who were not exposed. However, future long-term, larger or national data sets combined with genes, environmental exposure, lifestyle changes, dietary habits, and accurately defined PD diagnosis should be investigated to support the current research results.
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